The widened net loss is not reflective of operational deterioration but a non-cash accounting item. The improved cash runway and upcoming clinical catalysts (GTB-5550 initiation, Q3 2026 data update) may support investor sentiment, but the small market cap ($13M) and history of losses suggest high risk. Monitor for future funding needs and clinical data.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $0.4670entry
- T+1 · 9mo ago +0.64%α +1.56% · $0.4700
- T+5 · 8mo ago −10.71%α −9.50% · $0.4170
- T+20 · 8mo ago −11.35%α −3.41% · $0.4140
- T+60 · 6mo ago −16.06%α −25.39% · $0.3920
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GT Biopharma reported its 2025 financial results, showing reduced R&D and operating losses but a sharply higher net loss due to a $15.2M non-cash charge tied to preferred stock valuation. The company has $7M in cash as of year-end 2025, with a proforma balance of $9M in January 2026, funding operations through Q4 2026. Clinical progress includes ongoing GTB-3650 enrollment and FDA clearance for GTB-5550, with a trial expected to start mid-2026.
Key Facts
- Cash and cash equivalents: $7M as of December 31, 2025; unaudited proforma cash of $9M as of January 31, 2026
- Net loss: $28.4M in 2025 vs. $13.2M in 2024, driven by a $15.2M non-cash expense from preferred stock valuation
- R&D expenses decreased to $3.5M from $5.8M due to lower production costs
- Loss from operations improved to $12.4M from $14.4M
- SG&A expenses flat at ~$8.5M
- GTB-3650 Phase 1 trial ongoing, with Cohort 5 (25 µg/kg/day) expected to start in Q2 2026; next data update expected Q3 2026
- FDA cleared IND for GTB-5550 in January 2026; Phase 1 basket trial expected to initiate mid-2026
Financial Impact
Net loss widened by $15.2M due to non-cash charge; operating loss improved by $2M. Cash runway extended to Q4 2026 with $9M proforma balance.
Risk Factors
- Company faces going concern risk as noted in forward-looking statements
- High net loss despite lower operating expenses due to non-cash items may concern investors
- Need for future capital raises could lead to dilution
- Clinical trial delays could impact timeline and funding runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247203 |
Track record
12 reports on GTBP
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +41.62% at T+60 after the Aug 14, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 3/10 Entry $3.72 Now $3.54 −4.97% settles Feb 12
- Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
- Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
- Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
- Sep 15, 20268w ago 8-K Bearish 7/10 Entry $9.00 Now $3.54 +60.72% settles Dec 9
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
- Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
- May 22, 202625w ago 8-K Bearish 7/10 Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
- Apr 30, 202628w ago S-1 Bearish 7/10 Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers